Acutaas Chemicals Limited has released its corporate presentation for the upcoming investor conferences scheduled between May 27 and June 16, 2026. The company's officials will physically attend these conferences to interact with investors and analysts through one-on-one and group meetings across Mumbai, Hong Kong, Singapore, and London. The disclosure was filed on May 16, 2026, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Investor Conference Schedule

The company has outlined participation in four distinct conference events. The following table provides a detailed overview of the scheduled interactions:

Financial Performance

The corporate presentation highlights the company's financial performance for FY26. Revenue from operations for FY26 stood at ₹ 13,394 Mn, compared to ₹ 10,069 Mn in FY25. The company reported a Profit After Tax (PAT) of ₹ 3,564 Mn for FY25, with a PAT margin of 26.6% for FY26. The EBITDA for FY25 was ₹ 4,804 Mn, with an EBITDA margin of 35.9% for FY26.

Business Overview

Acutaas Chemicals operates across four primary segments: Pharmaceutical Intermediates, Semiconductor Chemicals, Battery Chemicals, and Commodity Chemicals. The company holds a 50-90% global market share in key intermediates and is the only manufacturer in India for photoresist chemicals. The presentation notes that the company is investing ₹ 1000+ Cr. for sustainable future growth from FY23 to FY30, including significant capex in Pharma, Battery, and Semiconductor segments.

Key Disclosures

Acutaas Chemicals has clarified that no unpublished price-sensitive information is intended to be discussed during any of the aforesaid conferences. The company has also noted that the above schedule may be subject to changes. The corporate presentation is available on the company's website.

Acutaas Chemicals has reported its financial results for the fourth quarter and fiscal year ended March 31, 2026. The company achieved its highest ever Profit After Tax (PAT) of INR356.4 crores for FY26, with revenue from operations reaching INR1,339.4 crores. Building on this strong performance, the management has expressed confidence in delivering 25% revenue growth in FY27.

Financial Performance for FY26

The company closed the fiscal year with robust financial metrics, reflecting significant year-on-year growth. The Managing Director highlighted that the results demonstrate the strength of their business model and disciplined execution.

Strategic Initiatives and Growth Drivers

Management outlined progress across multiple verticals to support future growth. In the battery chemicals business, the company has commercialized its first two products and expects to bring two additional products to commercial scale in FY27. The semiconductor business, particularly through BFC, is gaining traction with new products expected to contribute meaningfully in the coming year. Additionally, the R&D centre for the South Korea joint venture, Indichem, is operational and has started sending samples to prospective customers.

FY27 Outlook and Guidance

Acutaas Chemicals has guided for 25% revenue growth in FY27. This projection is backed by a strong pipeline across all three verticals: pharmaceutical intermediates, battery chemicals, and semiconductors. The management indicated that while near-term cost pressures from global supply chain disruptions exist, they are confident in maintaining EBITDA margins at levels similar to FY26. The company also noted that its existing infrastructure is well-positioned to support growth through FY28.